Leadership Changes at MDxHealth
IRVINE, CA, and HERSTAL, BELGIUM – MDxHealth SA (NASDAQ: MDXH) has made significant strides recently by welcoming Michael Holder to its Board of Directors as the new Chair of the Audit Committee. This appointment coincides with the completion of Regine Slagmulder’s term, recognizing her contributions to the board.
Michael Holder's Impressive Background
With over three decades of experience in various leadership roles, Mr. Holder brings a wealth of knowledge to the table. His career includes positions such as CEO and CFO in multiple biotech and health tech companies, showcasing his mastery in corporate governance, strategic planning, and operational efficiency. Prior to joining MDxHealth, Holder was the CEO of Sensable Health and has served on the board of Cytek Biosciences Inc. (NASDAQ: CTKB), exhibiting a robust understanding of the industry.
Comments from the MDxHealth Leadership
Michael K. McGarrity, the CEO of MDxHealth, expressed enthusiasm about Holder’s appointment. He stated, "We are incredibly excited to welcome Michael Holder to our Board of Directors as the Chair of our Audit Committee. His extensive background in the biotech and medtech fields will serve us well as we aim to enhance our growth in the urology markets we engage with."
Interim CFO Appointment
In addition to Mr. Holder's appointment, MDxHealth announced that Ron Kalfus will step down as Chief Financial Officer to explore new opportunities. Kalfus will remain in his position until July 30, 2025. Following his departure, Scott McMahan, the current Vice President of Finance and Accounting, will temporarily assume CFO responsibilities.
Reflections on Contributions
McGarrity also expressed gratitude towards Kalfus, noting, "On behalf of MDxHealth, I would like to thank Ron for his partnership and contributions during a significant growth period for our company. His involvement has been instrumental in our strategy and success."
About MDxHealth
MDxHealth is a leader in precision diagnostics, emphasizing the delivery of actionable molecular information that can significantly enhance patient diagnosis and treatment. The company's innovative tests utilize proprietary genomic and epigenetic technologies to assist healthcare professionals in diagnosing urologic cancers effectively. MDxHealth operates main laboratories in both Irvine, California, and Plano, Texas, with its European headquarters situated in Herstal, Belgium. For those interested in keeping up with MDxHealth, further information can be found on their website.
Frequently Asked Questions
What recent changes were made in MDxHealth's leadership?
MDxHealth appointed Michael Holder as the new Chair of the Audit Committee and announced Ron Kalfus' resignation as CFO.
What is Michael Holder's background?
Michael Holder has over 30 years of experience in biotech and health tech sectors, holding multiple executive positions and board roles.
Who is taking over as CFO after Ron Kalfus leaves?
Scott McMahan, the current Vice President of Finance and Accounting, will assume the CFO responsibilities on an interim basis.
How does MDxHealth assist healthcare professionals?
The company provides diagnostic tests that utilize advanced genomic and epigenetic technologies to diagnose urologic cancers.
Where are MDxHealth's main operations located?
MDxHealth has its U.S. headquarters in Irvine, California, and also operates laboratories in Plano, Texas, along with its European headquarters in Herstal, Belgium.
